Opus Genetics to Participate in Chardan’s 9th Annual
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or…
Opus Genetics Reports Inducement Grant Under Nasdaq Listing
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical…
Opus Genetics Inherited Retinal Disease Programs Featured
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company…
Opus Genetics and the Global RDH12 Alliance Partner to
Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE…